Brivaracetam (BRV) is a selective, high-affinity ligand for synaptic vesicle protein 2A (SV2A), recently approved as adjunctive treatment for drug-refractory partial-onset seizures in adults. BRV binds SV2A with higher affinity than levetiracetam (LEV), and was shown to have a differential interaction with SV2A. Because LEV was reported to interact with multiple excitatory and inhibitory ligand-gated ion channels and that may impact its pharmacological profile, we were interested in determining whether BRV directly modulates inhibitory and excitatory ionotropic receptors in central neurons. Voltage-clamp experiments were performed in primary cultures of mouse hippocampal neurons. At a supratherapeutic concentration of 100 lM, BRV was devoid of any direct effect on currents gated by c-aminobutyric acidergic type A, glycine, kainate, N-methyl-D-aspartate, and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. Similarly to LEV, BRV reveals a potent ability to oppose the action of negative modulators on the inhibitory receptors. In conclusion, these results show that BRV contrasts with LEV by not displaying any direct action on inhibitory or excitatory postsynaptic ligand-gated receptors at therapeutic concentrations and thereby support BRV's role as a selective SV2A ligand. These findings add further evidence to the validity of SV2A as a relevant antiepileptic drug target and emphasize the potential for exploring further presynaptic mechanisms as a novel approach to antiepileptic drug discovery. KEY WORDS: Brivaracetam, GABA, Glycine, NMDA, AMPA, Kainate.
Brivaracetam (BRV; Briviact) is a novel antiepileptic drug (AED) identified through rational drug design, following the discovery of levetiracetam (LEV; Keppra). 1 It was recently approved as adjunctive therapy in adults with refractory partial-onset seizures. LEV and BRV share binding to the synaptic vesicle protein 2A (SV2A), 2 and both modulate the presynaptic release of neurotransmitters leading to reduced neuronal excitability. 1 However, BRV displays a 15-30-fold higher affinity than LEV in binding to the native or recombinant SV2A protein 3 and was recently reported to also reveal a differential interaction to SV2A from LEV. 2 These findings appear to translate into superior potency for BRV in enhancing synaptic short-term depression during high-frequency stimulation and superior efficacy in reducing vesicle release during low-frequency stimulation in excitatory hippocampal neuronal networks. 4 This correlates with previous findings showing BRV to possess a different pharmacological profile from LEV in preclinical seizure and epilepsy models consisting of both more potent and more complete seizure suppression. 1 BRV also differentiates from LEV by faster brain entry and free brain concentrations at therapeutic oral doses for BRV (C max = 14 lM, 100 mg) 2 that are much lower than for LEV (C max = 422 lM; 1,500 mg). 5 However, several reports suggest additional mechanisms for LEV that involve inhibition of voltage-gated K + and Ca 2+ channels, 1, 6 which may influence the generation of action potentials and presynaptic neurotransmitter release. BRV further differentiates from LEV by the lack of activity on major voltage-gated ion channels. An initial study with BRV suggested significant inhibition of voltage-gated Na + channels in primary cortical neurons, but this effect was not confirmed in adult hippocampal neurons. 1 Likewise, repetitive neuronal firings in primary cortical neurons and adult hippocampal neurons were not impacted by BRV treatment, supporting the hypothesis that inhibition of voltage-gated Na + currents does not contribute to the antiepileptic mechanism of BRV. 1 Other studies revealed that BRV did not modulate ionic conductances in neurons, including high-and lowvoltage-activated Ca 2+ currents, voltage-gated delayed rectifier K + currents, and persistent voltage-gated Na + currents. 7 The study of the molecular mechanisms of LEV has also been extended to the impact on inhibitory postsynaptic receptors, indicating that LEV experimentally modulates caminobutyric acid type A (GABA A ) and glycine receptor activity by reversing the inhibitory effect of negative allosteric modulators such as beta-carbolines and zinc. 8 At therapeutic concentrations, LEV induced a small reduction in the peak amplitude and a prolongation of the decay phase of GABA-gated currents in hippocampal neurons. LEV did not show any direct effect on glycine-gated currents. Additional studies on excitatory postsynaptic receptors indicated that LEV does not modulate kainate-or N-methyl-D-aspartate (NMDA)-induced currents (up to 1 mM) but significantly inhibited a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-gated currents (IC 50 = 268 lM).
9 AMPA receptor modulation produced by 200 lM LEV was later confirmed in cultured cortical neurons. 10 The modulation of postsynaptic receptors by LEV prompted this study to explore potential modulation by BRV of inhibitory and excitatory postsynaptic receptors. We analyzed the effects of BRV (10-100 lM) on native ligand-gated ion channels in hippocampal neurons, including GABA A , glycine, kainate, NMDA, and AMPA receptors.
Methods
Hippocampal neurons were obtained from 16-day-old mouse embryos using methods fully described previously. 11 Cell dissociation and suspension were prepared as previously described. 8 The medium was renewed once weekly, and the cells were used for electrophysiological recordings after 7-14 days in vitro (DIV), except for studying the inhibition by methyl-6,7-dimethoxy-4-ethylb-carboline-3-carboxylate (DMCM) of glycine-induced currents, which is only observed in immature neurons. (NBQX), GABA, strychnine, bicuculline, and picrotoxin were purchased from Sigma (U.S.A.). DMCM was from RBI (U.S.A.). Glycine was purchased from UCB (Belgium). Voltage-clamp recordings were performed with a BioLogic RK-400 patch-clamp amplifier using the tight-seal whole-cell recording configuration. Series resistances were in the range 10-20 MΩ and were electronically compensated (up to 85-90%). Current traces were digitized and stored on a personal computer. Control of drug application, data acquisition, and data analysis were achieved using an ITC-16 acquisition board (Instrutech Corporation, U.S.A.) and TIDA for Windows software (HEKA Elektronik, Pf€ olz, Germany). Data analysis and graphing were made using GraphPad Prism software (U.S.A.). Except when stated otherwise, the results are expressed as mean AE standard error of the mean. Statistical significance of the data was assessed with Student t test or analysis of variance followed by Dunnett multiple comparison post-tests when significance was reached. In all experiments, differences were considered statistically significant when p < 0.05.
Results
Brivaracetam does not modify NMDA-, kainate-, or AMPA-gated currents Cultured hippocampal neurons (7-14 DIV) were used to investigate the effect of BRV on glutamate receptors. When recorded in voltage-clamp mode, only cultured neurons displaying fast inactivating inward currents and delayed rectified currents and no run-down of their glutamate responses were further taken into consideration. NMDA, AMPA, and kainate were applied at concentrations near their EC 50 values (determined in separate experiments as 9 lM for NMDA, 2 lM for AMPA, and 340 lM for kainate), together with increasing concentrations of BRV (Fig. 1A) . Figure 1 shows that up to a concentration of 100 lM, BRV does not influence the currents gated by these different ionotropic GluR agonists.
Brivaracetam does not modify inhibitory amino acidgated currents in cultured hippocampal neurons
In a previous study also involving hippocampal neurons, 8 we reported weak, but significant, modulatory effects of LEV on GABA-induced currents (reduction of peak amplitude from 1 lM, increase in decay time constant from 100 lM). The effect of BRV on GABA-and glycineinduced currents was therefore assessed by applying GABA and glycine at their EC 50 concentrations (12 lM for GABA and 108 lM for glycine) in the presence of increasing BRV concentrations. We observed that both the apparent kinetics of the GABA and glycine currents (activation and decay; Fig. 2A ) and their peak amplitudes are not significantly modified in the presence of BRV from 1 to 100 lM (Fig. 2B ).
Brivaracetam reverses zinc and DMCM inhibition of inhibitory amino acid-gated currents in cultured hippocampal neurons
The main interaction of LEV with inhibitory amino acid receptors was its ability to reverse the negative allosteric modulation of GABA and glycine responses evoked by zinc and b-carbolines. 8 The present study similarly investigated the effect of BRV (Fig. 2C-F) . Under control conditions, the addition of zinc produced an inhibition of GABA-and glycine-evoked currents of 23 AE 4% and 34 AE 6%, respectively. Fig. 2C ,D shows that BRV, at concentrations from 1 to 100 lM, reverses the inhibition induced by zinc of GABA-and glycine-induced currents. This effect is observed for concentrations of BRV as low as 1 lM. Fig. 2E,F shows that the inhibitory effect of DMCM on GABA and glycine responses is also reversed by BRV. This effect was visible from a BRV concentration of 1 lM for GABA responses and 10 lM for the reversal of DMCM effects on glycine responses.
Discussion
In this study, we investigated the functional effects of BRV on neuronal ligand-gated excitatory and inhibitory receptors and demonstrated that BRV does not inhibit NMDA-, AMPA-, kainate-, GABA-, and glycine-evoked currents at concentrations up to 100 lM. Previous studies have predicted that the exposure levels for BRV in the therapeutic dose range (50 mg twice daily) should reach~10 lM in the brain of patients, 3, 12 suggesting that the highest BRV concentrations used in this study (100 lM) represent a supratherapeutic dose. We therefore conclude that BRV does not modulate these ligand-gated ion channels at therapeutic brain concentrations, a finding that is consistent with BRV's antiepileptic properties being mediated by its selective action on the presynaptic SV2A protein.
In contrast to the absence of effects of BRV on direct receptor stimulation, BRV significantly reversed the modulation of GABA and glycine receptors by zinc and DMCM. 
Effect of brivaracetam (BRV) on glutamate-induced currents. (A)
Seven to 14 days in vitro hippocampal neurons were perfused for 10 s with a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA; 3 lM), kainate (100 lM), or N-methyl-D-aspartate (NMDA; 50 lM) as indicated, alone or in combination with BRV (100 lM). (B) Currents evoked by 3 lM AMPA, 100 lM kainate, or 50 lM NMDA (concentrations that elicit a half-maximal response) were recorded in the presence of increasing BRV concentrations. Results are expressed as percentage of excitatory amino acid-induced current peak amplitudes in the absence of BRV (mean AE standard error of the mean). Numbers of recorded neurons are indicated in graph bars. Analysis of variance followed by Dunnett multiple comparison post-tests yielded no significant effect up to 100 lM BRV. KA, kainic acid. Epilepsia ILAE These effects occurred in a concentration range of 1-10 lM, confirming a similar pattern as previously described for LEV, 8 although BRV produced these effects at 10-30-fold lower concentrations than LEV. Further research will be needed to address how relevant such a mechanism is in contributing to the anticonvulsant properties of AEDs. The lack of effects of BRV on excitatory and inhibitory receptors contrasts with the effects of LEV. Indeed LEV was shown to reduce the peak amplitudes of GABA currents and to inhibit AMPA currents in a concentration range that is relevant for its therapeutic use. 10 The latter mechanism is shared with topiramate and perampanel and coincides with these three AEDs, being associated with significant induction of neuropsychiatric adverse effects that limits their clinical use Results are expressed as percentage of GABA-and glycine-induced current peak amplitudes in the absence of any drug (mean AE SEM). Numbers of recorded neurons are indicated in graph bars. *p < 0.05, **p < 0.01 using ANOVA followed by Dunnett multiple comparison post-tests. Epilepsia ILAE in epilepsy patients. 13 This supports the hypothesis that the behavioral adverse effects, observed in a subgroup of patients exposed to LEV, 14 may at least partly derive from its inhibition of AMPA receptors. The lack of effects of BRV on AMPA receptors may therefore confer it a lower potential for induction of behavioral adverse effects in patients with epilepsy. The latter seems supported by a preliminary clinical study 15 that reported a major benefit of switching LEV-treated patients with behavioral adverse effects to BRV treatment. It remains to be determined whether this mechanistic hypothesis can provide a causal reason for induction of behavioral adverse effects. In conclusion, LEV and BRV show a distinct preclinical profile. 1 From a mechanistic perspective, this may reflect that BRV differs from LEV by higher affinity and a distinct interaction with SV2A contrasted by absence of other significant target interactions. The latter is supported by the findings of this study, which also provide a mechanistic rationale for expecting high tolerability and low incidence of behavioral adverse effects with BRV in patients with epilepsy. Further elucidation of presynaptic mechanism dysfunctions may provide new insights into the pathophysiological mechanisms of epileptic disorders.
